See more : TWC Tech Holdings II Corp. (TWCT) Income Statement Analysis – Financial Results
Complete financial analysis of BridgeBio Pharma, Inc. (BBIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BridgeBio Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Stryker Corporation (0R2S.L) Income Statement Analysis – Financial Results
- SI Capital & Financial Services Limited (SICAPIT.BO) Income Statement Analysis – Financial Results
- Univacco Technology Inc. (3303.TWO) Income Statement Analysis – Financial Results
- ShiftPixy, Inc. (PIXY) Income Statement Analysis – Financial Results
- New Dover Capital Corp. (NDVR) Income Statement Analysis – Financial Results
BridgeBio Pharma, Inc. (BBIO)
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 9.30M | 77.65M | 69.72M | 8.25M | 40.56M | 0.00 | 0.00 |
| Cost of Revenue | 2.45M | 3.43M | 3.11M | 3.09M | 2.50M | 0.00 | 260.00K |
| Gross Profit | 6.86M | 74.21M | 66.60M | 5.16M | 38.06M | 0.00 | -260.00K |
| Gross Profit Ratio | 73.71% | 95.58% | 95.53% | 62.57% | 93.84% | 0.00% | 0.00% |
| Research & Development | 455.71M | 402.90M | 454.14M | 337.05M | 209.95M | 140.07M | 30.56M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 145.68M | 94.35M | 43.59M | 13.30M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 150.59M | 143.19M | 192.21M | 145.68M | 94.35M | 43.59M | 13.30M |
| Other Expenses | 7.93M | 100.45M | 35.82M | 1.63M | -1.21M | -1.29M | 0.00 |
| Operating Expenses | 614.23M | 546.09M | 646.35M | 482.73M | 304.30M | 183.66M | 43.86M |
| Cost & Expenses | 616.67M | 546.09M | 646.35M | 482.73M | 306.80M | 183.66M | 43.86M |
| Interest Income | 18.04M | 7.54M | 1.13M | 4.02M | 8.92M | 2.00M | 39.00K |
| Interest Expense | 81.29M | 80.44M | 46.78M | 36.66M | 8.77M | 2.55M | 13.00K |
| Depreciation & Amortization | 6.49M | 6.77M | 5.84M | 3.09M | 859.00K | 245.00K | 260.00K |
| EBITDA | -565.47M | -397.44M | -533.83M | -465.75M | -279.82M | -183.42M | -43.56M |
| EBITDA Ratio | -6,078.34% | -455.49% | -774.11% | -5,683.51% | -688.87% | 0.00% | 0.00% |
| Operating Income | -607.37M | -471.87M | -579.75M | -474.48M | -266.24M | -183.66M | -43.86M |
| Operating Income Ratio | -6,528.75% | -607.71% | -831.58% | -5,751.99% | -656.41% | 0.00% | 0.00% |
| Total Other Income/Expenses | -45.88M | 27.55M | -9.82M | -31.01M | -22.35M | 14.21M | 26.00K |
| Income Before Tax | -653.25M | -484.65M | -586.45M | -505.49M | -288.59M | -169.45M | -43.83M |
| Income Before Tax Ratio | -7,021.94% | -624.17% | -841.20% | -6,127.87% | -711.50% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 9.31M | 52.84M | -21.56M | -28.15M | 16.76M | -13.49M |
| Net Income | -643.20M | -493.96M | -639.30M | -483.93M | -260.44M | -130.75M | -30.57M |
| Net Income Ratio | -6,913.92% | -636.16% | -917.00% | -5,866.47% | -642.10% | 0.00% | 0.00% |
| EPS | -3.95 | -3.35 | -4.43 | -4.10 | -2.48 | -1.42 | -0.33 |
| EPS Diluted | -3.95 | -3.35 | -4.43 | -4.10 | -2.48 | -1.42 | -0.33 |
| Weighted Avg Shares Out | 162.79M | 147.47M | 144.36M | 118.00M | 105.10M | 92.33M | 92.33M |
| Weighted Avg Shares Out (Dil) | 162.79M | 147.47M | 144.36M | 118.00M | 105.10M | 92.33M | 92.33M |
BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA
BridgeBio to stop development of therapy for genetic disorder
BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)
BridgeBio Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio: With HELIOS-B Overhang Removed, Focus To Turn To Approval And Launch Of Acoramidis
BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension
BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024
BridgeBio Pharma to Participate in September Investor Events
BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence
Source: https://incomestatements.info
Category: Stock Reports